Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Hone Health, a virtual longevity care platform, has secured $228M in combined equity and growth financing to expand its AI-driven, physician-led offerings. The company plans to add metabolic health programming, peptide therapies, advanced diagnostics, and clinical trial infrastructure. With 200,000 patients treated and $100M+ in 2025 revenue, Hone is positioning longevity medicine as the future of primary care.
Hone Health, a physician-led virtual longevity care platform, has raised $228 million — a combination of a $28M Series A extension led by MarcyPen Capital Partners and $200M in growth financing from General Catalyst's Customer Value Fund. The company plans to use the funds to expand clinical programming in metabolic health, inflammation, and immunity, launch a physician-supervised peptide program, and build out clinical trial infrastructure for pharma partnerships.
At its core, Hone's model starts with a $65 panel testing 70 biomarkers, followed by a clinician consult. Patients can then subscribe for $150/month (plus medication costs), with an AI system continuously personalizing treatment recommendations. The platform also unveiled Hone Black, a concierge longevity membership analyzing over 1,600 health markers and offering prescriptions, peptides, exosome, and stem cell therapies.
By the Numbers:
Why it matters: Hone's rapid growth signals a broader shift in how Americans are seeking and paying for healthcare — outside traditional systems. By blending AI, longitudinal data, and virtual physician care, Hone is betting that personalized longevity medicine can scale into mainstream primary care, particularly for patients underserved by conventional medicine.